Bladder Cancer

These FAQs outline key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.

The PDUFA target action date is in the fourth quarter of 2026.

Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.

Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

A decision is expected by the fourth quarter of 2026.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in patients with MIBC with complete response to neoadjuvant therapy.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.

Datopotamab deruxtecan will be assessed alone and in combination with rilvegostomig as adjuvant treatment for patients with high-risk muscle-invasive urothelial carcinoma.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

Nima Almassi, MD, reviews long-term evidence for bladder preservation after systemic therapy in muscle-invasive bladder cancer.

A claims-based analysis found blue light cystoscopy was associated with increased health care resource use in NMIBC without significantly increasing total costs.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.

Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.

Phase 3 BOND-003 data published in Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.